Agile Therapeutics (NASDAQ:AGRX) Trading Up 7.4%

Agile Therapeutics Inc (NASDAQ:AGRX) traded up 7.4% during trading on Wednesday . The company traded as high as $1.59 and last traded at $1.46, 2,085,268 shares were traded during trading. An increase of 410% from the average session volume of 408,884 shares. The stock had previously closed at $1.36.

Several brokerages have weighed in on AGRX. Maxim Group set a $3.00 price target on shares of Agile Therapeutics and gave the company a “buy” rating in a report on Monday, June 10th. Oppenheimer began coverage on shares of Agile Therapeutics in a research note on Thursday, June 6th. They issued an “outperform” rating and a $5.00 price objective for the company. Zacks Investment Research raised shares of Agile Therapeutics from a “hold” rating to a “strong-buy” rating and set a $1.25 price objective for the company in a research note on Tuesday, August 6th. Finally, ValuEngine downgraded shares of Agile Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the stock. Agile Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $3.45.

The firm has a market capitalization of $62.47 million, a PE ratio of -2.52 and a beta of 0.42. The company has a 50-day moving average price of $1.16 and a 200 day moving average price of $1.32.

Agile Therapeutics (NASDAQ:AGRX) last released its earnings results on Thursday, August 1st. The specialty pharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. As a group, research analysts predict that Agile Therapeutics Inc will post -0.37 EPS for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. boosted its stake in Agile Therapeutics by 2,219.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 76,538 shares of the specialty pharmaceutical company’s stock worth $108,000 after purchasing an additional 73,238 shares during the period. Geode Capital Management LLC raised its position in shares of Agile Therapeutics by 24.0% during the fourth quarter. Geode Capital Management LLC now owns 230,496 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 44,639 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Agile Therapeutics by 27.2% in the second quarter. BlackRock Inc. now owns 169,226 shares of the specialty pharmaceutical company’s stock worth $247,000 after buying an additional 36,212 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Agile Therapeutics by 33.3% in the first quarter. Acadian Asset Management LLC now owns 417,269 shares of the specialty pharmaceutical company’s stock worth $630,000 after buying an additional 104,222 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Agile Therapeutics by 129.8% in the second quarter. Vanguard Group Inc. now owns 1,732,648 shares of the specialty pharmaceutical company’s stock worth $2,530,000 after buying an additional 978,672 shares in the last quarter. 43.73% of the stock is currently owned by institutional investors.

About Agile Therapeutics (NASDAQ:AGRX)

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.

Featured Story: Understanding Relative Strength Index

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit